Work

A novel bispecific adaptor platform enhances CD19-CAR T cell persistence and efficacy in solid tumors

Year: 2026
Type: preprint
Abstract: Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment but remains ineffective in solid tumors. Here, we compared CD19-CAR and HER2-CAR T cells with identical backbones in matched tumor models. Strikingly, CD19-CAR T cells eradicated all tested CD19 + solid tumors in vivo , whereas HER2-CAR T cells failed to control matched HER2 + solid tumors. Superior CD19-CAR efficacy was associated with greater avidity, stronger signaling, and rapid degranulation. To harness these favorable properties for solid tumor treatment, we developed and compared bispecific Adaptors redirecting CD19-CAR T cell activity against HER2 + cancers. Our lead nanobody-based Adaptor 4 incorporating an albumin-binding VHH improves upon earlier designs by enhancing manufacturability and tumor infiltration while retaining systemic persistence. It induced complete tumor regression and prolonged survival in two solid tumor models. Mechanistically, Adaptor 4 enhanced CAR T cell-tumor cell engagement, signaling and intratumoral infiltration, accompanied by spatially distinct CAR T cell states and local inflammatory remodeling. Long-term tumor-free mice rejected tumor rechallenge, demonstrating durable antitumor protection. Importantly, Adaptor 4 remained effective when combined with CD19-CAR T cells generated from patients with advanced solid cancers. Together, these findings establish an enhanced Adaptor strategy redirecting clinically validated CD19-CAR T cells for solid tumor treatment.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7234941041
Cites: 25
Cited by:
Related to: 10